NVO Stock Summary and Trading Ideas (Novo Nordisk A/S | NYSE:NVO)

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk A/S trades on the NYSE stock market under the symbol NVO.

As of November 4, 2026, NVO stock price climbed to $42.18 with 21,104,312 million shares trading.

NVO has a beta of 0.90, meaning it tends to be less sensitive to market movements. NVO has a correlation of 0.05 to the broad based SPY ETF.

NVO has a market cap of $186.09 billion. This is considered a Large Cap stock.

Last quarter Novo Nordisk A/S reported $12 billion in Revenue and $.96 earnings per share. This beat revenue expectation by $859 million and exceeded earnings estimates by $.15.

In the last 3 years, NVO traded as high as $148.15 and as low as $35.12.

The top ETF exchange traded funds that NVO belongs to (by Net Assets): PPH, AVDE, WCMI, FENI, PID.

NVO has underperformed the market in the last year with a return of -10.3%, while the SPY ETF gained +13.3%. In the last 3 month period, NVO fell short of the market, returning -9.2%, while SPY returned +1.5%. However, in the most recent 2 weeks NVO has outperformed the stock market by returning +7.2%, while SPY returned -0.3%.

NVO support price is $39.64 and resistance is $40.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVO shares will trade within this expected range on the day.